A Long-Chain Dextran Produced by Boosts the Diversity of Health-Related Gut Microbes Ex Vivo
Overview
Authors
Affiliations
Long-chain dextrans are α-glucans that can be produced by lactic acid bacteria. NextDext, a specific long-chain dextran with a high degree of polymerisation, produced using , was recently shown to exert prebiotic potential in vitro. In this study, the ex vivo SIFR technology, recently validated to provide predictive insights into gut microbiome modulation down to the species level, was used to investigate the effects of this long-chain dextran on the gut microbiota of six human adults that altogether covered different enterotypes. A novel community modulation score (CMS) was introduced based on the strength of quantitative 16S rRNA gene sequencing and the highly controlled ex vivo conditions. This CMS overcomes the limitations of traditional α-diversity indices and its application in the current study revealed that dextran is a potent booster of microbial diversity compared to the reference prebiotic inulin (IN). Long-chain dextran not only exerted bifidogenic effects but also consistently promoted spp., and butyrate-producing species like and . Further, long-chain dextran treatment resulted in lower gas production compared to IN, suggesting that long-chain dextran could be better tolerated. The additional increase in for dextran compared to IN is likely related to the higher propionate:acetate ratio, attributing potential to long-chain dextran for improving metabolic health and weight management. Moreover, the stimulation of butyrate by dextran suggests its potential for improving gut barrier function and inflammation. Overall, this study provides a novel tool for assessing gut microbial diversity ex vivo and positions long-chain dextran as a substrate that has unique microbial diversity enhancing properties.
Chen X, Guo X IET Syst Biol. 2025; 19(1):e12114.
PMID: 39846370 PMC: 11771788. DOI: 10.1049/syb2.12114.
Mercenier A, Vu L, Poppe J, Albers R, McKay S, Van den Abbeele P Metabolites. 2024; 14(12).
PMID: 39728503 PMC: 11678764. DOI: 10.3390/metabo14120722.
Bifidogenic Effect of Human Milk Oligosaccharides on Pediatric IBD Fecal Microbiota.
Otaru N, Bajic D, Van den Abbeele P, Velde S, Van Biervliet S, Steinert R Microorganisms. 2024; 12(10).
PMID: 39458287 PMC: 11509818. DOI: 10.3390/microorganisms12101977.
Advances in Microbial Exopolysaccharides: Present and Future Applications.
Nguyen H, Pham T, Nguyen P, Le-Buanec H, Rabetafika H, Razafindralambo H Biomolecules. 2024; 14(9).
PMID: 39334928 PMC: 11430787. DOI: 10.3390/biom14091162.
Deyaert S, Poppe J, Vu L, Baudot A, Bubeck S, Bayne T Metabolites. 2024; 14(9).
PMID: 39330504 PMC: 11433953. DOI: 10.3390/metabo14090497.